Imatinib: Paradigm or anomaly?

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The introduction of imatinib (Gleevec, Glivec, formerly STI571), an agent targeting the causative molecular event in chronic myeloid leukemia (CML) has been heralded as a major advance in the treatment of cancer. Certainly, the clinical trials with imatinib have validated the concept that a precise understanding of the pathogenesis of a cancer can lead to more effective and less toxic therapies. Despite the success of imatinib, there remains much skepticism that this paradigm will be applicable to more complicated solid tumors. Whether this skepticism is appropriately deserved will be discussed.

Original languageEnglish (US)
Pages (from-to)831-833
Number of pages3
JournalCell Cycle
Issue number7
StatePublished - Jul 2004


  • Chronic myeloid leukemia
  • Gastrointestinal stromal tumor
  • Gefitinib
  • Imatinib
  • Lung cancer

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Imatinib: Paradigm or anomaly?'. Together they form a unique fingerprint.

Cite this